Lantern Pharma Inc Stock Price, News & Analysis

Lantern Pharma (NASDAQ: LTRN) announced it will present new preclinical data at three scientific conferences: the Society of Neuro Oncology Annual Meeting on November 18, the San Antonio Breast Cancer Symposium on December 8, and the American Society of Hematology Annual Meeting on December 10. A key focus will be the preclinical efficacy of LP-184, a therapeutic targeting glioblastoma. Lantern Pharma leverages its proprietary RADR® platform to identify patients likely to benefit from its targeted therapies, which could significantly enhance treatment outcomes.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced its participation in the ThinkEquity Conference on October 26, 2022, in New York, NY. Lantern's CEO, Panna Sharma, is set to host an A.I. and Drug Development Panel at 10:00 a.m. ET, discussing the role of A.I. in enhancing oncology drug development. Lantern is scheduled to present at 1:00 p.m. ET, with a webcast available for viewers. The company aims to leverage its RADR® A.I. platform to optimize drug discovery and development timelines.

Lantern Pharma (NASDAQ: LTRN) has secured U.S. Patent No. 11,471,431 for its drug candidate LP-300, aimed at enhancing survival in cancer patients with overexpressed thioredoxin or glutaredoxin. This patent extends commercial protection until late 2032, fostering potential partnerships and new cancer treatment programs. LP-300 is currently in a Phase 2 clinical trial for relapsed non-small cell lung cancer (NSCLC) patients. The drug has previously shown significant survival improvements in clinical trials.

Lantern Pharma (NASDAQ:LTRN), a clinical-stage biopharmaceutical company, is set to present at the MicroCap Rodeo Windy City Roundup 2022 on October 12 at 11:00 a.m. ET. CEO Panna Sharma will lead the presentation, which will be live-streamed and available for replay. Lantern Pharma leverages its proprietary RADR^® platform for oncology drug discovery, focusing on developing targeted therapeutics based on patient genomic profiles. Attendees can schedule one-on-one meetings with the management team throughout the event.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, is utilizing its RADR^® A.I. platform to enhance oncology drug development. The company will present at two investor conferences: the MicroCap Rodeo in Chicago, IL on October 12 at 10:00 a.m. CT, and the ThinkEquity Conference in New York, NY on October 26 at 10:30 a.m. ET. CEO Panna Sharma will lead both presentations, highlighting Lantern's focus on targeting therapies to patient-specific genomic profiles.

Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present preclinical data on its drug candidate LP-284 for mantle cell lymphoma (MCL) at the SOHO Tenth Annual Meeting from Sept. 28 to Oct. 1, 2022. LP-284 has demonstrated strong anti-tumor potency in MCL and other non-Hodgkin's lymphomas, particularly against Ibrutinib and Bortezomib-resistant cell lines. The company plans to submit an IND for LP-284 in Q1 2023 and launch a Phase 1 clinical trial in Q2 2023, aiming to capitalize on a $200 million annual market.

Lantern Pharma (NASDAQ: LTRN) announced a virtual key opinion leader webinar on September 22, 2022, at 12:00 p.m. ET. The webinar will address challenges in drug development for pediatric cancers and feature Dr. Peter Houghton, an expert from Greehey Children's Cancer Research Institute. He will discuss disparities in pediatric cancer research and present preliminary results for drug candidates LP-184 and LP-284. Registration details are available, with a replay on Lantern's website from September 23, 2022.

Lantern Pharma Inc. (NASDAQ: LTRN) announced the presentation of positive preclinical data for its drug candidate LP-184 targeting pancreatic cancer at the AACR Special Conference from Sept 13-16, 2022. The drug, which preferentially damages cancer cells with DDR gene mutations, demonstrated significant efficacy, achieving tumor growth inhibitions of 140% and 112% in mouse models. LP-184 has received Orphan Drug Designation from the FDA, with plans for IND submission in Q1 2023 and Phase 1 trials expected in Q2 2023.

Lantern Pharma Inc. (NASDAQ: LTRN) announces that CEO Panna Sharma will present at H.C. Wainwright’s 24th Annual Global Investment Conference from September 12-14, 2022, in New York, NY. Lantern Pharma utilizes its RADR^® AI platform to enhance oncology drug discovery, focusing on genomically targeted therapeutics. The company is currently developing four drug candidates across nine tumor targets. Details on registration and webcasting are provided for interested investors.